APBB2

Across TCGA pan-cancer cohorts, APBB2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated APBB2 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher APBB2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated APBB2 expression acts as an unfavorable survival marker.

LUAD, COAD, and LSCC are the cancer types where APBB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.487	1.000	.016	14	view →
COAD	DFS	Median	III,IV	0.808	1.000	.027	12	view →
LSCC	OS	Median	II,III,IV	0.662	0.879	.014	12	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

APBB2–LUAD (DFS)

Open the LUAD breakdown →